As a widely used neuroendocrine marker, CD56 is highly sensitive to neuroendocrine tumours [28–30], speculating that ccRCC may be a tumour with neuroendocrine characteristics, and CD56 has the potential to be a marker for assisting the diagnosis of ccRCC. Here, NCAM1 is linked to neuroendocrine neoplasm.